rs6010620

This functional study identifies rs3761124 as a causal variant on 20q13.33 that modulates glioma risk through enhancer activity and altered expression of multiple genes, particularly STMN3. Using luciferase assays, CRISPR-Cas9 editing, and eQTL analysis across 646 individuals from brain tissue and tumor cohorts, the authors demonstrate that rs3761124 has allele-specific effects on enhancer activity and consistently associates with STMN3 expression. Colocalization analysis (PP4=0.82) supports rs3761124 as the causal variant underlying the GWAS signal at this locus.

This case-control study examined 5 SNPs in the RTEL1 gene (regulator of telomere elongation helicase 1) in 596 coronary heart disease (CHD) patients and 603 healthy controls from a Chinese Han population. Two SNPs showed protective associations: rs6010620 (OR = 0.78, 95% CI = 0.65-0.93, p = 0.005) and rs4809324 (OR = 0.08, 95% CI = 0.04-0.16, p = 2.74E-21). Haplotype analysis revealed the 'GTT' haplotype of three RTEL1 SNPs was associated with significantly decreased CHD risk (OR = 0.03, 95% CI = 0.01-0.12, p < 0.0001).

This study investigated the association of MGMT enhancer variant rs11016629 with glioma susceptibility and progression in 402 patients and 654 controls. The TG genotype was associated with increased glioma risk (OR=1.41, 95% CI 1.03-1.93, P=0.034), particularly in WHO grade IV tumors (OR=1.59, P=0.023). In patients who underwent gross total resection, carriers with TG/TT genotypes had worse progression-free survival (HR=2.66, 95% CI 1.23-5.79, P=0.014) compared to GG carriers.

This study examined genetic variant interactions in atopic dermatitis using data from 4,636 Chinese Han cases and 13,559 controls. Four SNPs showed significant interactions: rs17173197 (PRKAG2) × rs3126085 (FLG) with P=1.11E-15, rs17173197 × rs7701890 (TMEM232-SLC25A46) with P=2.22E-15, rs17173197 × rs6010620 (TNFRSF6B-ZGPAT) with P=6.66E-16, and a three-way interaction among these loci with P=5.99E-15.

A case-control study examining seven known glioma risk loci in individuals with a family history of brain tumours (104 FHBT-glioma cases, 2,868 controls). Three SNPs were associated with glioma risk: rs2736100 (TERT; OR=1.41, 95% CI 1.05-1.89), rs4977756 (CDKN2A-CDKN2B; OR=2.01, p=0.01), and rs6010620 (RTEL1; OR=0.51, p=0.012 for glioblastoma). Only rs6010620 remained significant after correction for multiple comparisons.

Genome-wide association study of glioma in 1,856 cases and 4,955 controls that confirmed seven previously reported susceptibility loci. Strong replication was found for rs2736100 (TERT, OR=0.72), rs4977756 (CDKN2BAS, OR=1.35), and rs6010620 (RTEL1, OR=0.66). Consistent associations were observed for loci at EGFR, CCDC26, and PHLDB1. Meta-analysis of 85 candidate loci in 5,015 cases and 11,601 controls identified no novel genome-wide significant associations, suggesting glioma genetic architecture may involve fewer common variants than other cancers.

This review discusses recent genome-wide association studies (GWAS) that identified five susceptibility loci for glioma: TERT rs2736100 (OR=1.27), CCDC26 rs4295627 (OR=1.36), CDKN2A/CDKN2B rs4977756 (OR=1.24), RTEL1 rs6010620 (OR=1.18), and PHLDB1 rs498872 (OR=1.28). The combined effect shows that individuals with 8 or more risk alleles have over 3-fold increased glioma risk compared to those with median alleles (OR=1.31 per allele, p=1.39×10^-74). These common low-risk variants represent the strongest evidence to date for inherited susceptibility to glioma, with shared associations across multiple cancer types.